- Home
- TGB vs IRWD Comparison
TGB vs IRWD Comparison
Compare TGB & IRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TGB
- IRWD
- Stock Information
- Founded
- TGB 1966
- IRWD 1998
- Country
- TGB Canada
- IRWD United States
- Employees
- TGB N/A
- IRWD N/A
- Industry
- TGB Precious Metals
- IRWD Biotechnology: Pharmaceutical Preparations
- Sector
- TGB Basic Materials
- IRWD Health Care
- Exchange
- TGB Nasdaq
- IRWD Nasdaq
- Market Cap
- TGB 633.3M
- IRWD 716.9M
- IPO Year
- TGB N/A
- IRWD 2010
- Fundamental
- Price
- TGB $2.08
- IRWD $3.34
- Analyst Decision
- TGB Strong Buy
- IRWD Buy
- Analyst Count
- TGB 1
- IRWD 4
- Target Price
- TGB $3.50
- IRWD $12.00
- AVG Volume (30 Days)
- TGB 5.6M
- IRWD 1.5M
- Earning Date
- TGB 11-06-2024
- IRWD 11-07-2024
- Dividend Yield
- TGB N/A
- IRWD N/A
- EPS Growth
- TGB 17.58
- IRWD N/A
- EPS
- TGB 0.12
- IRWD N/A
- Revenue
- TGB $439,681,705.00
- IRWD $378,418,000.00
- Revenue This Year
- TGB $19.57
- IRWD N/A
- Revenue Next Year
- TGB $15.05
- IRWD N/A
- P/E Ratio
- TGB $17.83
- IRWD N/A
- Revenue Growth
- TGB 25.87
- IRWD N/A
- 52 Week Low
- TGB $1.15
- IRWD $3.31
- 52 Week High
- TGB $3.15
- IRWD $15.70
- Technical
- Relative Strength Index (RSI)
- TGB 42.31
- IRWD 33.13
- Support Level
- TGB $1.95
- IRWD $3.96
- Resistance Level
- TGB $2.12
- IRWD $5.07
- Average True Range (ATR)
- TGB 0.12
- IRWD 0.33
- MACD
- TGB -0.02
- IRWD -0.12
- Stochastic Oscillator
- TGB 20.97
- IRWD 1.70
About TGB Taseko Mines Ltd.
Taseko Mines Ltd is a Canadian mining company. It is principally engaged in the production and sale of metals, as well as related activities, including exploration and mine development, within the province of British Columbia, Canada, and the State of Arizona, the United States. The Gibraltar, Aley, New Prosperity, Yellowhead properties are located in British Columbia whereas Florence copper is in central Arizona.
About IRWD Ironwood Pharmaceuticals Inc.
Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.